Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The backbone of therapy for chronic lymphocytic leukemia (CLL) is the combination of fludarabine and cyclophosphamide (FC). In order to exert its cytotoxic effect, cyclophosphamide must first be converted to its active form by CYP2B6, an isoform of cytochrome P450.
In this week's issue of Blood, Johnson and colleagues present a study discussing the impact of genetic variation in CYP2B6 on CLL response to FC regimens by screening for the most common variant of CYP2B6 that defines the *6 allele. The results demonstrate important implications for pharmacogenetic analysis influencing individualized dosing and/or choice of therapeutic agents in the future.
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia, Gillian G. Johnson, Ke Lin, Trevor F. Cox, Melanie Oates, David R. Sibson, Richard Eccles, Bryony Lloyd, Laura-Jayne Gardiner, Daniel F. Carr, Munir Pirmohamed, Jonathan C. Strefford, David G. Oscier, David Gonzalez de Castro, Monica Else, Daniel Catovsky, and Andrew R. Pettitt, Blood - doi: 10.1182/blood-2013-07-516666
Article adapted by Medical News Today from original press release. Source:
Please use one of the following formats to cite this article in your essay, paper or report:
Blood. "CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia." Medical News Today. MediLexicon, Intl., 24 Dec. 2013. Web.
7 Mar. 2014. <http://www.medicalnewstoday.com/releases/270592>
Blood. (2013, December 24). "CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270592.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.